BN-101A blocks programmed cell death ligand 1 (PD-L1) function and promotes anti-cancer T- cell activity. The drug has been validated in preclinical models and BioEleven plans to enter a global phase I clinical trial by 2022.

Under the agreement, Samsung Biologics will provide the full scope of its development services including cell line development, process development, nonclinicial and clinical material manufacturing, and regulatory filing support.

Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy
Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.

PharmAbcine, Samsung Biologics expand partnership
PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody...

Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.